TLR9-Targeted Nanoparticle Conjugates for MDS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myelodysplastic syndromes (MDS), particularly those without a chromosome 5q deletion, lack effective targeted therapies, leading to reliance on frequent blood transfusions and non-specific chemotherapy with severe side effects and limited benefits, contributing to the disease's burden and increased risk of acute myeloid leukemia transformation.
Innovation Solution
Development of compositions and methods targeting TLR9-expressing cancer cells using nanoparticles conjugated with TLR9 ligands, such as unmethylated CpG oligodeoxynucleotides, that selectively target and kill malignant cells by internalizing cytotoxic agents, minimizing toxicity outside cells and avoiding engulfment by macrophages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific chemotherapy is used to treat MDS patients without del5q, then some therapeutic effect may be achieved, but severe side effects and limited benefit occur
Solution Approach 1:
The treatment is segmented into two components: a targeting ligand (unmethylated CpG oligodeoxynucleotide) that specifically binds to TLR9 on MDS cells, and a cytotoxic agent (doxorubicin). This segmentation allows the cytotoxic agent to be delivered specifically to target cells, reducing exposure to healthy cells and thereby reducing severe side effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The TLR9-targeting ligand acts as an intermediary that mediates the delivery of the cytotoxic agent to MDS cells. The ligand binds to TLR9 receptors on the surface of MDS cells, facilitating selective internalization of the conjugated cytotoxic agent, thereby achieving targeted therapy that reduces harm to non-target cells.
2Adaptability or versatility
If targeted therapy with TLR9 ligands is developed, then specific treatment for non-del5q MDS can be achieved, but development complexity and resource requirements increase
Solution Approach 1:
The patent utilizes the universal TLR9 receptor that is expressed on the surface of MDS cells without del5q as a target. By conjugating a known TLR9 ligand (unmethylated CpG oligodeoxynucleotide) with a cytotoxic agent, the invention creates a versatile targeted therapy platform that can be applied to TLR9-positive cancers, reducing development complexity through leveraging existing biological knowledge and tools.
3Quantity of substance
If frequent blood transfusions are administered to MDS patients, then transfusion dependence is maintained, but disease burden and risk of AML transformation increase
Solution Approach 1:
The invention extracts and eliminates the underlying malignant MDS cells through targeted cytotoxic therapy, rather than merely replacing blood cells through transfusions. By specifically killing TLR9-positive MDS cells, the treatment removes the source of the disease burden and reduces the risk of AML transformation, while potentially reducing the need for frequent transfusions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces TLR9+ cell populations, including hematopoietic stem cells, thereby providing a targeted therapeutic option for MDS and other TLR9-positive cancers, potentially reducing transfusion dependence and transforming the treatment landscape for MDS patients.
Implementation Method 1
molecules containing TLR9 targeting ligands that target nanoparticles to TLR9-expressing malignant cells
Implementation Method 2
This cationic structure of the nanoparticle/polymer can be cytotoxic once internalized by a cell, but non-toxic outside the cell
Data Source
AI summary
Disclosed are compositions and methods for targeted treatment of TLR9-expressing cancers. In particular, disclosed herein are molecules or conjugates containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, and a cytotoxic nanoparticle that targets TLR9-expressing malignant cells. Also disclosed is a pharmaceutical composition comprising a molecule disclosed herein in a pharmaceutically acceptable carrier. Also disclosed is a method for treating a TLR9-positive cancer in a subject that involves administering to the subject a therapeutically effective amount of a disclosed pharmaceutical composition.